Bladder cancer is among the most expensive diseases in oncology in terms of treatment costs; each procedure requires days of hospitalisation and recurrence rates are high. Current unmet clinical needs can be addressed by optical methods due to the combination of non-invasive and real-time capture of unprecedented biomedical information.
The MIB objective is to provide robust, easy-to-use, cost-effective optical methods with superior sensitivity and specificity to enable a step-change in point-of-care diagnostics of bladder cancer. The concept relies on combining optical methods providing structural, biochemical and functional information. The hypothesis is that such combination enables in situ diagnosis of bladder cancer with superior sensitivity and specificity due to unprecedented combined anatomic, biochemical and molecular tissue information. The step-change is that this hybrid concept is provided endoscopically for in vivo clinical use.
The project relies on development of new light sources, high-speed imaging systems, unique imaging fibre bundles, and endoscopes, combined and applied clinically. The consortium comprises world-leading academic organisations in a strong partnership with innovative SMEs and clinical end-users.
Through commercialization of this novel imaging platform, MIB is expected to reinforce leading market positions in medical devices and healthcare for the SMEs in areas where European industry is already strong. The impact is that improved diagnostic procedures facilitate earlier onset of effective treatment, thus recurrence and follow-up procedures can be reduced, resulting in reduced costs. Equally important, prognosis and patient quality of life improves drastically.